Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Eugene R. Ahn,Pam K. Mangat,Elizabeth Garrett-Mayer,Susan Halabi,Elie G. Dib,Daniel Haggstrom,Kathryn B. Alguire,Ricardo H. Alvarez,Carmen Julia Calfa,Timothy Lewis Cannon,Pamela A. Crilley,Anu G. Gaba,Alissa S. Marr,Ashish Sangal,Ramya Thota,Kaitlyn R. Antonelli,Samiha Islam,Andrew Lawrence Rygiel,Suanna S. Bruinooge,Richard L. Schilsky

Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

2019

9041Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort ...

Keywords:

Palbociclib
Cohort
non-small cell lung cancer (NSCLC)
Pathology
CDKN2A
Oncology
Internal medicine
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations